The morbidity and mortality of AL amyloidosis is caused by the deposition of Ig light chains as amyloid protein in vital organs. With conventional therapy median survival of patients with AL amyloidosis is 10-14 months. With high-dose chemotherapy clinical remissions of organ-specific disease have been reported. Here, we present a patient with high-risk AL amyloidosis who was given high-dose therapy and a peripheral blood stem cell transplant. Four days later she died of gastrointestinal perforation due to amyloid infiltrations. Keywords: AL amyloidosis; blood stem cell transplantation; gastrointestinal perforation AL amyloidosis is a plasma cell dyscrasia that derives from an excess production of immunoglobulin light chains which form insoluble amyloid deposits in almost every organ system. Renal involvement leading to nephrotic syndrome and congestive heart failure are the most common presentations of AL amyloidosis. Median survival is 10-14 months and drops to 4 months for patients with congestive heart failure.
AL amyloidosis is a plasma cell dyscrasia that derives from an excess production of immunoglobulin light chains which form insoluble amyloid deposits in almost every organ system. Renal involvement leading to nephrotic syndrome and congestive heart failure are the most common presentations of AL amyloidosis. Median survival is 10-14 months and drops to 4 months for patients with congestive heart failure. [1] [2] [3] Since conventional-dose chemotherapy has been shown to be ineffective, 4 high-dose therapies with subsequent peripheral blood stem cell (PBSC) support have been used in these patients. Here, we report a patient with AL amyloidosis given high-dose therapy and experiencing a rare and lethal complication.
Case report
After presenting with nephrotic syndrome, AL amyloidosis with kappa light chain infiltration in a renal biopsy was diagnosed in a 43-year-old female Caucasian in October 1995. Bone marrow (BM) aspirations in November 1995 and April 1996 were normal. In February 1996, the patient began therapy with interferon alpha and prednisone. The latter was discontinued after 5 months due to side-effects. In October 1996, the patient experienced increasing pain in both legs with full movement and paraesthesia of the toes and tongue. In December 1996 she was admitted to our hospital for re-evaluation of the disease. A BM biopsy with immunohistochemical staining showed an infiltration of 6% plasma cells which were IgD/lambda positive. She had increasing proteinuria of 8-9 g/24 h, edema, hypoalbuminemia with normal creatinine and urea. Monoclonal IgD/lambda light chains were found in both urine and peripheral blood (PB) by immunofixation electropheresis. Electrocardiogram showed low voltage. Echocardiography and magnetic resonance imaging showed massive concentric biventricular hypertrophy. The left ventricular technetium ejection fraction of the heart was normal at 75%. Serum chemistry and PB cell counts were normal. No hepatomegaly was found on CT scan, and the patient had no gastrointestinal complaints. In conclusion, the patient had an AL amyloidosis with involvement of kidneys, heart, peripheral nerves and bone marrow. In view of the patient's young age and excellent performance status, and the poor prognosis of AL amyloidosis, the decision to perform an autologous peripheral blood stem cell transplant (PBSCT) was made. After informed consent she received recombinant human granulocyte colony-stimulating factor (rh G-CSF) 10 g/kg/day subcutaneously for 5 days for PBSC mobilization. Then, 8.0 ϫ 10 6 CD34-positive cells/kg body weight were collected on 3 days by leukapheresis.
Twelve weeks later she received melphalan 200 mg/m 2 over 2 days followed by PBSC infusion and G-CSF at 5 g/kg/day continuously i.v. starting on day ϩ1. During and after conditioning she repeatedly complained of nausea and emesis. On day ϩ3 after PBSCT she presented with severe hematemesis, epigastric pain, anemia, thrombocytopenia and hypovolemia. Red blood cell and platelet transfusions were given. Esophago-gastro-duodenoscopy revealed fresh blood in the pyloric region and a 2.5 cm diameter ulcer in the duodenum Forrest IIb. Despite analgesia, omeprazol and strict intravenous fluid and nutritional support her abdominal pain increased. One day later surgery revealed a 1.5 cm perforation in the jejunum and a highly friable gut mucosa. Immunohistochemical analysis of the jejunum showed amyloid deposits of lambda-light chains that exhibited birefringence under polarized light and stained congo red positive predominantly in the lamina propria ( Figure 1 ). Three hours after surgery the patient died. Autopsy revealed amyloid infiltration in the gut (Figure 2) , kidneys, liver, heart, spleen, lungs and adrenal glands.
Discussion
The observations of an increase in atypical plasma cells in BM in this patient, along with light chain proteinuria and congestive heart failure, indicated high-risk AL amyloidosis and thus, an extremely poor prognosis. 3 Conventional therapy had no impact on her disease. 4 Because of disease progression and good clinical performance status Figure 2 Histologic section of small bowel demonstrating the presence of amyloid as evidenced by extracellular deposits of an amorphous glassy red substance within the lamina propria. Note that only a few degenerated colonocytes may be observed in one crypt, while the remainder has been effaced secondary to ischemia. Original magnification ϫ 400.
high-dose therapy was suggested. To avoid myocardial side-effects, cyclophosphamide-based PBSC mobilization or conditioning therapy were not given. With G-CSF stimulation alone an excellent yield of PBSC was obtained allowing timely hematopoietic regeneration after high-dose therapy, as described. 5 Since melphalan has been reported to effect marked improvements in AL amyloidosis, this conditioning therapy was given. Durable complete remissions of plasma cell dyscrasias and rapid reversals of cardiac or neurologic disease have been seen in these patients. [6] [7] [8] To minimize the risks of intermittent aplasia, extensive supportive care including antimicrobial prophylaxis with nonabsorbable antibiotics, Pneumocystis carinii prophylaxis and adequate blood cell support were administered to our patient. Furthermore, G-CSF was given after PBSC infusion to decrease the time to neutrophil recovery as previously reported. 9 The gastrointestinal tract is known to often be infiltrated with amyloid, leading to dysphagia, bowel obstruction, diarrhea, diffuse abdominal discomfort and weight loss. 4, 10, 11 Acute perforation of the small bowel has been reported in patients with amyloid deposits in the muscle layers of the intestinal wall. 10 Furthermore, deaths due to gastrointestinal hemorrhage have occasionally been seen with amyloid deposits within the walls of submucosal and mesenteric arteries. 3, 10 Anecdotal reports suggest a higher transplant-related mortality in patients transplanted for multiple myeloma associated with amyloidosis. Recently, Mehta et al 12 reported a massive gastrointestinal hemorrhage in a patient with multiple myeloma occurring 3 days after high-dose chemotherapy. This lethal event is comparable to our observation.
To date, few data about the impact of gastrointestinal involvement on eligibility for intensive treatments are available. In view of the complication observed in our patient, thorough radiologic examination of the gastrointestinal region is advisable. Markedly abnormal radiologic small bowel examinations have been found in patients without intestinal symptoms. 10 Since rectal biopsies are known to be positive in patients with AL amyloidosis when amyloid deposits are demonstrable in various gastrointestinal areas, this procedure could allow detection of wide-spread disease with acceptable discomfort. Due to lack of data, however, the impact of extensive gut involvement on transplant-associated mortality cannot currently be assessed for certain. Whether the benefit of high-dose therapy and PBSCT outweigh the risks of some complications as seen in our case must be decided on a case-by-case basis. Furthermore, administration of high-dose therapy followed by PBSC infusion at an early disease stage prior to extensive multiorgan infiltration seems to be advisable.
